March 20th Options Now Available For Clorox (CLX)

Clorox (CLX) trades at $110.71 with a $110 put bidding $4.80 (implying a net purchase basis of $105.20) and a $115 call bidding $3.20; the $110 put is ~1% out-of-the-money and the $115 call ~4% out-of-the-money. Analytics show a 54% probability the put expires worthless (YieldBoost of 4.36%, 24.90% annualized) and a 60% probability the covered call expires worthless (premium boost 2.89%, 16.50% annualized); the call’s assigned scenario to $115 through the March 20th expiration yields 6.77% excluding dividends. Implied volatilities are 34% (put) and 30% (call) versus a trailing 12-month volatility of 24%, suggesting option premiums price in elevated short-term risk relative to realized volatility.

Analysis

Market structure: The options market is currently rewarding sellers — the CLX Mar20 $110 put yields $4.80 (4.36% cash yield, 24.9% annualized) and the $115 covered call yields $3.20 (2.89%, 16.5% annualized). That favors income-focused accounts, broker flows, and market-makers collecting premium; equity holders face capped upside if they write calls. The 1% OTM put and 4% OTM call with market odds of 54%/60% expiring worthless signal a modestly range-bound market view for CLX over the next ~64 days (to Mar 20).

Risk assessment: Implied vol (put 34%, call 30%) is meaningfully above realized TTM vol (24%) — put IV is ~42% higher vs realized, creating a skew opportunity but also signalling event risk priced by markets. Near-term (days–weeks) the biggest risks are earnings, CPI/consumer data and trade promotions that can gap price >5%; short-term (months) inventory/shelf-price adjustments and input-cost swings drive margins; long-term threats include category disruption or persistent volume declines. Tail risks: sharp consumer spending shock or margin surprise could push CLX well below the $105–$110 ladder and force large assignment/hedging flows for option sellers.

Trade implications: Direct actionable plays are option-selling and covered-call income because IV > realized: sell-to-open CLX Mar20 $110 puts or buy-and-write (buy CLX at ~$110.71, sell $115 Mar20 calls). Size these trades so assignment equals no more than 1–2% portfolio exposure; use stop-losses if price drops >5% or IV spikes +10pt. Use pair trades (long CLX, short XLY or short discretionary names) to express defensive rotation and consider a 110/105 bull-put spread to cap downside when selling puts.

Contrarian angles: Consensus income trade underestimates gamma risk around earnings — IV could gap higher and punish naked sellers despite rich premium, so risk-adjusted returns are asymmetric. The market may be underpricing sustained realized volatility if consumer staples face renewed deflationary promotions; that would make buying protection or buying volatility on a pullback preferable to naked selling. Historical parallels (staples IV rich vs realized) show sellers earn carry but incur episodic large losses; structure positions accordingly.

Key Decisions for Investors

• Sell-to-open CLX Mar20 $110 puts at current bid ($4.80) sized so maximum assignment equals 1% of NAV (e.g., 100 shares per contract per $100M NAV = trivial exposure); target effective entry $105.20; close if CLX < $102 or IV > +10 vol points to limit tail losses.
• Buy 100–300 shares CLX (~$110.71) and sell-to-open Mar20 $115 calls (collect $3.20) as a buy-write yielding 6.77% to 16.5% annualized; allocate 1–2% portfolio and unwind if share price > $117 before expiry to capture extra upside.
• If you want defined risk, trade a Mar20 110/105 bull-put spread (sell $110 put / buy $105 put) targeting net credit ≥ $2.00; this limits downside to $3.00 per share and keeps positive carry while cutting tail risk.
• Implement a relative-value defensive pair: long CLX (or buy-write) vs short XLY (equal dollar, net exposure 0.5–1% NAV) to express staples over discretionary for 1–3 month horizon; trim if CPI or retail sales surprise to the upside by >0.3ppt.